Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, GLP-1RA + Basal Feb 01 | 2019Novo to File Oral Sema with PRV; Q4 '18 Earnings UpdatePurchase Blast
$599
Posted in: Glucose Monitoring Jan 31 | 2019New Roche Smartphone BGM; Q4 '18 Earnings UpdatePurchase Blast
$599
Posted in: Glucose Monitoring Jan 31 | 2019Senseonics Receives MRI Approval for Eversense Implantable CGMPurchase Blast
$599
Posted in: Glucose Monitoring, Other Jan 30 | 2019Livongo Acquires Behavioral Health CompanyPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Jan 29 | 2019Lilly Repeatedly Called Out During US Senate Hearing on Drug PricingPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Jan 25 | 2019Biocon CY Q4 '18 (FY Q3 '19) Earnings UpdatePurchase Blast
$599
Posted in: Glucose Monitoring Jan 23 | 2019Libre Reaches 1.3M Users; Abbott Q4 ’18 Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Other Jan 23 | 2019Oramed Initiates Ph1 Oral GLP-1RA; Zafgen and vTv Ph2 dataPurchase Blast
$599
Posted in: Bolus Insulin Jan 18 | 2019Thoughts on Afrezza Direct Purchase ProgramPurchase Blast$599
Posted in: SGLT2i Jan 18 | 2019Lexicon down ~24%; Post-adcom Call Summary and ThoughtsPurchase Blast$599
Posted in: SGLT2i Jan 17 | 2019Sota adcom vote split 8-8; on-time approval now in questionPurchase Blast$599
Posted in: GLP-1RA, SGLT2i Jan 17 | 2019New Trulicity Label Update: lower hypo cutoff, AWARD-10, and pre-filled syringe discontinuationPurchase Blast$599
Posted in: SGLT2i Jan 17 | 2019$LXRX Trading Halted Ahead of Sotagliflozin FDA AdcomPurchase Blast$599
Posted in: SGLT2i Jan 15 | 2019FENIX Analysis: Sotagliflozin FDA Adcom Briefing DocumentsPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, Glucagon, Insulin Delivery, SGLT2i Jan 08 | 2019JPM 2019 Day 2: LLY, SNY, LXRX, ABT, PODD, MYLPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
